> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pfizer to Submit Anti-Covid Paxlovid Data to FDA
- URL: https://www.fdaweb.com/pfizer-to-submit-anti-covid-paxlovid-data-to-fda/
- Published: 2021-12-08T12:00:00.000Z
- Updated: 2026-09-14T17:25:00.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150725

Pfizer CEO **Albert Bourla** told CNBC 12/8 that the company will submit full data on its Paxlovid oral anti-viral Covid pill to FDA within a few days. He said Pfizer hopes for an agency decision on the company’s November emergency use authorization request this month.

Bourla [said](https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=newssearch&cd=&cad=rja&uact=8&ved=2ahUKEwju8MrFzdT0AhVxneAKHR0hAlkQxfQBKAB6BAgGEAI&url=https%3A%2F%2Fwww.cnbc.com%2F2021%2F12%2F08%2Fpfizer-will-submit-full-data-on-covid-treatment-pill-to-the-fda-in-a-few-days-ceo-says.html&usg=AOvVaw2H50GZLTYYnwKLtO0EdlXx) he’s confident the data will show that Paxlovid reduces hospitalization and death by 89%. Paxlovid is taken in combination with the HIV drug ritonavir (AbbVie’s Norvir).